Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation
Article 2016 en
Authors
GC
Giulio Cavalli
MK
Marije I. Koenders
VK
Vassili Kalabokis
Abstract
1 min read
IL-37 emerges as a key suppressor of joint and systemic inflammation. These findings indicate a rationale for using recombinant IL-37 in the treatment of arthritis.
Giulio Cavalli, Marije Koenders, Vassili Kalabokis, Jihye Kim, Aik Choon Tan, Cecília Garlanda, Alberto Mantovani, Lorenzo Dagna, Leo A. B. Joosten, Charles A. Dinarello
Giulio Cavalli, Jamie N. Justice, Kristen E. Boyle, Angelo D’Alessandro, Elan Eisenmesser, Jonathan J. Herrera, Kirk C. Hansen, Travis Nemkov, Rinke Stienstra, Cecília Garlanda, Alberto Mantovani, Douglas R. Seals, Lorenzo Dagna, Leo A. B. Joosten, Dov B. Ballak, Charles A. Dinarello
Suzhao Li, C. Preston Neff, Kristina Barber, Jaewoo Hong, Yuchun Luo, Tania Azam, Brent E. Palmer, Mayumi Fujita, Cecília Garlanda, Alberto Mantovani, Soohyun Kim, Charles A. Dinarello
Claire Greenhill, Gareth W Jones, Mari A. Nowell, Zarabeth Newton, Ann K Harvey, Abdul Nazeer Moideen, Fraser L. Collins, Anja Bloom, Rebecca C. Coll, Avril A. B. Robertson, Matthew A. Cooper, Marcela Rosas, Philip R. Taylor, Luke O'neill, Ian R. Humphreys, Anwen S. Williams, Simon A. Jones
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.